Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of temocillin (BRL 17421), a novel beta-lactamase-stable penicillin.

Literature DB >> 6982023

In vitro activity of temocillin (BRL 17421), a novel beta-lactamase-stable penicillin.

Abstract

The new in vitro activity of temocillin (BRL 17421), a new beta-lactamase-stable penicillin, was compared with those of other beta-lactam antibiotics for over 500 clinical bacterial isolates. Temocillin inhibited 94% of the Enterobacteriaceae organisms at concentrations of 0.5 to 8 microgram/ml, regardless of organisms resistance to ampicillin, ticarcillin, cefazolin, or combinations thereof. Most pseudomonas aeruginosa isolates and all staphylococci and streptococci tested were resistant to temocillin.

Entities: Chemical Species

Mesh：

Substances：

Year: 1982 PMID： 6982023 PMCID： PMC183693 DOI： 10.1128/AAC.22.1.157

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

2 in total

1. BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

Authors: B Slocombe; M J Basker; P H Bentley; J P Clayton; M Cole; K R Comber; R A Dixon; R A Edmondson; D Jackson; D J Merrikin; R Sutherland
Journal: Antimicrob Agents Chemother Date: 1981-07 Impact factor: 5.191

2. GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.

Authors: L Verbist; J Verhaegen
Journal: Antimicrob Agents Chemother Date: 1980-05 Impact factor: 5.191

2 in total

18 in total

Review 1. Pharmacokinetics and Pharmacodynamics of Temocillin.

Authors: Kevin Alexandre; Bruno Fantin
Journal: Clin Pharmacokinet Date: 2018-03 Impact factor: 6.447

2. Influence of temocillin on human bowel flora.

Authors: H W Mittermayer
Journal: Drugs Date: 1985 Impact factor: 9.546

3. Antibacterial activity of temocillin in combination with other beta-lactam antibiotics.

Authors: L Verbist; J Verhaegen
Journal: Drugs Date: 1985 Impact factor: 9.546

4. Interpretive criteria for temocillin disk diffusion susceptibility testing.

Authors: P C Fuchs; A L Barry; C Thornsberry; R N Jones
Journal: Eur J Clin Microbiol Date: 1985-02 Impact factor: 3.267

5. Susceptibilities of 45 clinical isolates of Proteus penneri.

Authors: M Fuksa; S Krajden; A Lee
Journal: Antimicrob Agents Chemother Date: 1984-09 Impact factor: 5.191

6. In vitro combination-effect of temocillin with ticarcillin and aminoglycosides on gram-negative and gram-positive bacteria.

Authors: H M Just; C Becker; J Gieringer; A Wenz; M Bassler; F Daschner
Journal: Drugs Date: 1985 Impact factor: 9.546

In vitro activity of temocillin (BRL 17421), a novel beta-lactamase-stable penicillin.

1. BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

2. GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.

Review 1. Pharmacokinetics and Pharmacodynamics of Temocillin.

2. Influence of temocillin on human bowel flora.

3. Antibacterial activity of temocillin in combination with other beta-lactam antibiotics.

4. Interpretive criteria for temocillin disk diffusion susceptibility testing.

5. Susceptibilities of 45 clinical isolates of Proteus penneri.

6. In vitro combination-effect of temocillin with ticarcillin and aminoglycosides on gram-negative and gram-positive bacteria.

7. Temocillin in the treatment of gram-negative septicaemia.

8. Clinical evaluation of temocillin in urinary tract infections.

9. Temocillin treatment of serious infections due to gram-negative bacilli in an intensive care unit.

10. Effect of temocillin in combination with other beta-lactam antibiotics.